ArticleClinical ophthalmology (Auckland, N.Z.)2026
Real-World Study Assessing the Efficacy and Safety of a Novel KLEx Procedure with a Next-Generation Femtosecond Laser for Refractive Error Correction.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: ELITA Femtosecond Laser System (Johnson & Johnson) is a next-generation ophthalmic laser platform designed for Smooth Incision Lenticular Keratomileusis (SILK). A retrospective study evaluated refractive outcomes, visual acuity, higher-order aberrations (HOAs), tear film parameters, and dry eye symptoms 30 days postoperatively. Patients and Methods: A retrospective, non-comparative, case series analyzing real-world data from patients with myopia treated using the SILK procedure with the ELITA femtosecond laser. The study included 144 eyes from 73 consecutive patients (47 female, 26 male) with myopia (-4.51 ± 1.36 D; range -1.50 D to -8.250 D). Refraction and uncorrected distance visual acuity (UDVA) were assessed preoperatively and at 1, 7, and 30 days postoperatively. A subset of 18 patients (36 eyes) underwent additional evaluation of tear film (Keratograph, LipiView, Schirmer II, NIBUT), dry eye symptoms (OSDI), and HOAs/contrast sensitivity (iTrace). Results: At 30-days, 96.5% of eyes (139/144) achieved 20/20 UDVA while the remaining 3.5% achieved 20/25. The mean spherical equivalent was -0.22 ± 0.68 D. No significant changes were observed in tear film metrics, HOAs, or contrast sensitivity. A statistically significant difference in vertical coma was noted (0.05 ± 0.04 µm vs 0.1 ± 0.09 µm, P = 0.008), though not clinically relevant. No serious adverse events occurred. Conclusion: The SILK procedure with the ELITA femtosecond laser platform is safe and effective for myopia correction (with and without astigmatism), with no detrimental effect on tear film stability, dry eye symptoms, or visual quality at 30 days post-surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.